Compare · DXCM vs GKOS
DXCM vs GKOS
Side-by-side comparison of DexCom Inc. (DXCM) and Glaukos Corporation (GKOS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and GKOS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.10B, about 3.4x GKOS ($9.77B).
- Over the past year, DXCM is up 29.2% and GKOS is up 89.0% - GKOS leads by 59.7 points.
- GKOS has been more active in the news (7 items in the past 4 weeks vs 6 for DXCM).
- Both have 25 recent analyst ratings on file.
- Company
- DexCom Inc.
- Glaukos Corporation
- Price
- $86.05-1.93%
- $164.87-0.58%
- Market cap
- $33.10B
- $9.77B
- 1M return
- -2.13%
- +2.12%
- 1Y return
- +29.24%
- +88.96%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2005
- 2015
- News (4w)
- 6
- 7
- Recent ratings
- 25
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Glaukos Corporation
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Latest GKOS
- Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery
- Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases
- SEC Form 4 filed by Glaukos Corporation
- Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus
- Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28
- CHIEF DEVELOPMENT OFFICER Navratil Tomas sold $249,158 worth of shares (1,615 units at $154.28) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 70,818 units (SEC Form 4)
- Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus
- CHIEF DEVELOPMENT OFFICER Navratil Tomas sold $243,204 worth of shares (1,457 units at $166.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 72,433 units (SEC Form 4)
- CHIEF DEVELOPMENT OFFICER Navratil Tomas sold $2,483,104 worth of shares (13,744 units at $180.67), decreasing direct ownership by 16% to 73,890 units (SEC Form 4)
- Director Kliman Gilbert H exercised 2,500 shares at a strike of $25.77 and sold $475,000 worth of shares (2,500 units at $190.00) (SEC Form 4)